Patients with newly diagnosed unfavorable intermediate, high, or very-high-risk prostate cancer, biochemical recurrence, and castration-resistant prostate cancer (CRPC) represent the scenarios with the highest scores for PSMA imaging utilization (see Table 1) [2]. This evidence concerns the gene FOLH1 and prostate cancer.